MedInCell Stock Jumps 6% Midday After Technical Rebound
MedInCell's stock saw a sharp increase this Monday at midday, climbing 6.13% to 21.48 euros, amid a strong rebound in the Paris market. The Montpellier-based biopharmaceutical company's stock thus recovers some of the losses accumulated in recent months, after a decline of nearly 16% over three months. The CAC 40 is up 0.61% during the session, driven by a de-escalation of geopolitical tensions.
Technical Rebound from Support Level
MedInCell's stock has rebounded from the support threshold at 20.24 euros, exactly matching Friday's closing price. This level, tested at the end of last week, appears to have formed a short-term technical floor. However, the stock is still significantly below its 50-day (24.09 euros) and 200-day (23.24 euros) moving averages, indicating that the medium-term downward trend remains intact despite today's surge. The RSI, at 35, is near the oversold zone (below 30), a level that generally signals excessive selling pressure that could favor a corrective rebound. The most significant resistance is at 25.02 euros, about 18% above the current price. Over one year, the stock still maintains a positive performance of over 40%, reflecting the strong revaluation achieved during the past fiscal year.
Following a Dramatic Turnaround in the Paris Market
MedInCell's progress occurs in the wake of a dramatic turnaround in the Paris market this Monday. After dropping more than 2% in the morning due to sharp fears over the threat of US strikes against Iran, the CAC 40 abruptly reversed its course following the announcement by Washington of 'very successful' talks with Tehran and the postponement of military operations. The SBF 120 concurrently rose by 0.63% in session. Among comparable health sector stocks, Sanofi remains almost stable (+0.06%) while UCB is up by 0.89%. MedInCell's low beta (0.08) typically indicates a limited correlation with major indices, suggesting that today's movement could also reflect factors specific to the stock, including a technical buyback after several weeks of decline. On the financial calendar, the next major milestone for the company is the publication of its annual results for the fiscal year 2025-2026, scheduled for June 16, 2026.
